Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), rilpivirine/F/TAF (R/F/TAF) or F/TAF + another 3rd agent in HIV-1+patients over 24 months - Results from the German TAFNES cohort study

被引：0
|
作者：
Stellbrink, H. [1 ]
Scholten, S.
Hillenbrand, H. [2 ]
Knechten, H. [3 ]
Jessen, H.
Schreiber, S. [4 ]
Goerner, K. [4 ]
Haubrich, R. [5 ]
Heinzkill, M. [4 ]
机构：
[1] ICH Study Ctr Hamburg, Clin Care, Hamburg, Germany
[2] MVZ Praxis City Ost, Clin Care, Berlin, Germany
[3] PZB, Clin Care, Aachen, Germany
[4] Gilead Sci, Med Affairs, Munich, Germany
[5] Gilead Sci, Med Affairs, Foster City, CA USA
来源：
JOURNAL OF THE INTERNATIONAL AIDS SOCIETY | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
P050
引用
收藏
页码：54 / 55
页数：2
相关论文
共 50 条
  • [1] Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-naive HIV-1 infected patients-24-month results from the German TAFNES cohort study
    Pauli, R.
    Jessen, H.
    Postel, N.
    Heuchel, T.
    Rieke, A.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    [J]. HIV MEDICINE, 2019, 20 : 54 - 55
  • [2] 24-month evaluation of the German TAFNES cohort - Effectiveness, persistence and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), F/TAF+3rd agent or rilpivirine/F/TAF (R/F/TAF) in treatment-experienced HIV-1 infected patients
    Knechten, H.
    Schneeweiss, S.
    Schuebel, N.
    Hillenbrand, H.
    Kuemmerle, T.
    Schreiber, S.
    Goerner, K.
    Heinzkill, M.
    Haubrich, R.
    Stellbrink, H-J
    [J]. HIV MEDICINE, 2019, 20 : 60 - 61
  • [3] Effectiveness and persistence of F/TAF-containing regimens (E/C/F/TAF, R/F/TAF or F/TAF+3rd agent) in late and very late presenters: final 24-month results from the German TAFNES cohort study
    Postel, N.
    Jessen, H.
    Pauli, R.
    Hillenbrand, H.
    Heuchel, T.
    Rieke, A.
    Knechten, H.
    Emmerich, C.
    Schreiber, S.
    Mack, F.
    Haubrich, R.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 108 - 109
  • [4] Effectiveness and persistence of E/C/F/TAF, R/F/TAF or F/TAF+3rd agent in late and very late presenters-final 24 month results from the German TAFNES cohort study
    Postel, Nils
    Jessen, Heiko
    Pauli, Ramona
    Hillenbrand, Heribert
    Rieke, Ansgar
    Knechten, Heribert
    Stellbrink, Hans-Juergen
    Emmerich, Claudia
    Schreiber, Sandra
    Mack, Frank
    Haubrich, Richard
    [J]. INFECTION, 2021, 49 (SUPPL 1) : S16 - S17
  • [5] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF in treatment-experienced HIV-1 infected patients: 12-month results from the German TAFNES cohort study
    Hillenbrand, H.
    Knechten, H.
    Kuemmerle, T.
    Scholten, S.
    Schuebel, N.
    Haubrich, R.
    Heinzkill, M.
    Goerner, K.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [6] Effectiveness, persistence and safety of E/C/F/TAF, F/TAF+3rd agent or R/F/TAF use in treatment-naive HIV-1 infected patients: 12-month results from the German TAFNES cohort study
    Heuchel, T.
    Hillenbrand, H.
    Jessen, H.
    Pauli, R.
    Postel, N.
    Haubrich, R.
    Heinzkill, M.
    Goerner, K.
    Stellbrink, H.
    [J]. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [7] HIV-1/HCV Coinfection Treatment with Single-Tablet Antiviral Regimens (CoSTARs): 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) after Randomized Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Rilpivirine/F/TAF (R/F/TAF)
    Ramgopal, Moti
    Jain, Mamta K.
    Hinestrosa, Federico
    Asmuth, David
    Huhn, Gregory
    Slim, Jihad
    Goldstein, Deborah
    Ryu, Julie
    Jiang, Shuping
    Das, Moupali
    Piontkowsky, David
    Rossaro, Lorenzo
    Haubrich, Richard
    Nguyen-Cleary, Thai
    [J]. HEPATOLOGY, 2017, 66 (06) : 1262A - 1263A
  • [8] Safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected adults on chronic haemodialysis
    Eron, J.
    Kalayjian, R.
    Wurapa, A.
    Stephens, J.
    McDonald, C.
    Wilkin, A.
    McKellar, M.
    Custodio, J.
    Jiang, S.
    SenGupta, D.
    Castles, R.
    Das, M.
    [J]. HIV MEDICINE, 2018, 19 : S16 - S16
  • [9] Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in Virologically Suppressed Women Text
    Hodder, Sally
    Squires, Kathleen
    Kityo, Cissy
    Hagins, Debbie
    Avihingsanon, Anchalee
    Kido, Anna
    Jiang, Shuping
    Kulkarni, Rima
    Cheng, Andrew
    Cao, Huyen
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2018, 78 (02) : 209 - 213
  • [10] Efficacy and Safety of Co-formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF) in the Geriatric Adult with Renal Impairment
    Martorell, C.
    Ward, D.
    Short, W. S.
    Ramgopal, M.
    Das, M.
    Nguyen-Cleary, T.
    Shave, A.
    McCallister, S.
    [J]. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2017, 65 : S177 - S177
12345